COMMUNIQUÉS West-GlobeNewswire

BrightSpring Health Services, Inc. Reports Second Quarter 2024 Financial Results and Increases Full Year 2024 Guidance

02/08/2024 - 12:00

LOUISVILLE, Ky., Aug. 02, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]

The Ensign Group Acquires Skilled Nursing Facility in Iowa

02/08/2024 - 12:00

SAN JUAN CAPISTRANO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]

The Ensign Group Acquires Skilled Nursing Facility in Colorado

02/08/2024 - 12:00

SAN JUAN CAPISTRANO, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]

EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS

02/08/2024 - 07:30

EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ® GENOMIC TEST FROM MYRIAD GENETICS Paris, August 2 nd , 2024 –7:30 am Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro specialty [...]

EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DU TEST GÉNOMIQUE ENDOPREDICT® AUPRÈS DE MYRIAD GENETICS

02/08/2024 - 07:30

EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DU TEST GÉNOMIQUE ENDOPREDICT ® AUPRÈS DE MYRIAD GENETICS Paris, le 2 août 2024 –7h30 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le [...]

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

02/08/2024 - 02:31

Funding Extends Company’s Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised More than 300 Patients Enrolled in Ongoing SHIELD II [...]

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/08/2024 - 00:50

RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 12,300 [...]

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/08/2024 - 00:00

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics [...]

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

01/08/2024 - 22:30

ROCKVILLE, Md., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

01/08/2024 - 22:30

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving [...]

La FDA accorde le statut de médicament orphelin à CLLS52 (alemtuzumab) de Cellectis pour le traitement de la LLA

01/08/2024 - 22:30

NEW YORK, 01 août 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) (la « Société »), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome TALEN [...]

Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results

01/08/2024 - 22:30

● Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ● Q2 Test volume up 12% year-over-year to record levels ● Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ● Q2 Volume, Revenue [...]

The Pennant Group Announces New $250 Million Credit Facility

01/08/2024 - 22:21

EAGLE, Idaho, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the [...]

CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors

01/08/2024 - 22:15

Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential [...]

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

01/08/2024 - 22:15

WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies [...]

CooperCompanies Acquires obp Surgical, Expanding CooperSurgical’s Portfolio of Leading Medical Devices

01/08/2024 - 22:15

SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless [...]

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

01/08/2024 - 22:10

Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 VANCOUVER, British Columbia, Aug. 01, 2024 ( [...]

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

01/08/2024 - 22:10

– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO ® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating petosemtamab [...]

Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024

01/08/2024 - 22:10

ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced [...]